Details for Patent: 10,106,548
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 10,106,548 protect, and when does it expire?
Patent 10,106,548 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-five patent family members in thirty-one countries.
Summary for Patent: 10,106,548
Title: | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Abstract: | Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
Inventor(s): | Purro; Norbert (Los Gatos, CA), Smyth; Mark S. (Foster City, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC) |
Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
Application Number: | 15/900,660 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,106,548 |
Patent Claim Types: see list of patent claims | Formulation; Compound; |
Drugs Protected by US Patent 10,106,548
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Inc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,106,548
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 092844 | See Plans and Pricing | |||
Argentina | 118108 | See Plans and Pricing | |||
Australia | 2013271918 | See Plans and Pricing | |||
Australia | 2016250445 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |